Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
TG Therapeutics Inc(TGTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TGTX
11/09/2026: TGTX (5-star) is a STRONG-BUY. BUY for 49 days. Simulated Profits (13.00%). Updated daily EoD!
TG Therapeutics is a commercial-stage biotechnology company that has successfully brought its flagship drug, Briumvi, to market for the treatment of relapsing multiple sclerosis. Its primary strength lies in this approved asset and a management team focused on niche therapeutic areas. The company's growth story centers on increasing the market share of Briumvi against well-capitalized competitors. However, the company faces significant risks, including revenue concentration, high competition, and the need for ongoing operational efficiency to reach sustainable profitability. This stock is best suited for growth-oriented investors with a high risk tolerance who are closely monitoring commercial adoption rates and clinical development milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through product commercialization but carries the high risks associated with a smaller, single-product biopharma. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of accelerating Briumvi sales and positive clinical news flow. |
| Value investor | Weak fit | The stock currently lacks the earnings and asset base that typically attract value-oriented investors. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on growth and operational development. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile, making this an unsuitable fit for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial results, FDA decisions, and quarterly sales reports. |
| Valuation risk | Medium / high | Valuation relies heavily on future market penetration of Briumvi, which is subject to execution uncertainty. |
| Competition risk (Major Pharma) | High | Competing against established giants with deep pockets for marketing and patient support programs is a significant hurdle. |
| Business quality | Medium | While the company has a successful product, the limited diversification of the current revenue base creates concentration risk. |
| Dividend income | Low / none | Investors should expect no income and must rely solely on potential capital appreciation. |
| Execution risk | Medium / high | Success depends on the company's ability to navigate the complex commercial landscape of multiple sclerosis treatment. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 33.6% | Avg. Invested days 29 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.16B USD | Price to earnings Ratio 21.75 | 1Y Target Price 69.71 |
Price to earnings Ratio 21.75 | 1Y Target Price 69.71 | ||
Volume (30-day avg) 1.8M shares | Beta 1.81 | 52 Weeks Range 26.76 - 63.60 | Updated Date 11/08/2026 |
52 Weeks Range 26.76 - 63.60 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.75 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sales of Briumvi (ublituximab) for the treatment of relapsing forms of multiple sclerosis. | The company primarily makes money by selling its single approved drug to healthcare providers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-09 | When Before Market | Estimate 0.28 | Actual 0.35 |
Profitability
Profit Margin 55.22% | Operating Margin (TTM) 9.02% |
Management Effectiveness
Return on Assets (TTM) 7.28% | Return on Equity (TTM) 100.28% |
Valuation
Trailing PE 21.75 | Forward PE 27.7 | Enterprise Value 9.36B | Price to Sales(TTM) 11.45 |
Enterprise Value 9.36B | Price to Sales(TTM) 11.45 | ||
Enterprise Value to Revenue 11.71 | Enterprise Value to EBITDA 67.14 | Shares Outstanding 153.08M | Shares Floating 135.24M |
Shares Outstanding 153.08M | Shares Floating 135.24M | ||
Percent Insiders 7.47 | Percent Institutions 75.78 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.